Archive for July 17th, 2012

ZGNX PDUFA date confirmed. PATH resubmits NDA for migraine. HGSI to be acquired by GSK + MDGN RPRX updates

Jul 17, 2012 No Comments by

Zogenix, Inc. (Nasdaq:ZGNX) announced that the FDA has set a PDUFA date of March 1, 2013 for the Zohydro ER New Drug Application (NDA), for the treatment of moderate to severe chronic pain. NuPathe Inc. (NASDAQ: PATH) announced that it has resubmitted its NDA for its migraine patch (NP101), with a likely six-month review period by the FDA. GlaxoSmithKline plc (LSE: GSK) […]

Daily News Read more